The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute
Issue link: https://lifescienceleadermag.epubxp.com/i/140470
EDITORIAL ADVISORY BOARD John Baldoni Executive Coach, Leadership Educator Baldoni Consulting LLC Heather Erickson, President and CEO Life Sciences Foundation Norman Klein Principal, Core Results Rafik Bishara, Ph.D. Chair, Pharmaceutical Cold Chain Interest Group, PDA Jeffrey Evans, Ph.D. Life Science Entrepreneur Timothy Krupa President, TSK Clinical Development John LaMattina, Ph.D. Tim Freeman Senior Partner, PureTech Ventures Director of Operations at Freeman G. Steven Burrill Technology and Past Chair of the Process Eric Langer CEO & Founder, Burrill & Company Analytical Technology Focus Group of AAPS President and Managing Partner BioPlan Associates Ron Cohen, M.D. Laura Hales, Ph.D. President and CEO Founder, The Isis Group Lynn Johnson Langer, Ph.D. Acorda Therapeutics , Inc. Director, Enterprise and Fred Hassan Regulatory Affairs Program Laurie Cooke Chairman of the Board Center for Biotechnology Education CEO Johns Hopkins University Healthcare Businesswomen's Association (HBA) Bausch + Lomb John Hubbard, Ph.D. Alan Eisenberg Senior VP & Worldwide Head Executive VP, Emerging of Development Operations, Pfizer Companies and Bus. Dev. Biotechnology Industry Organization (BIO) Maik Jornitz Founder, BioProcess Resources, LLC Barry Eisenstein, M.D. Immediate Past Chair PDA Senior VP, Scientific Affairs Cubist Pharmaceuticals Mitchell Katz, Ph.D. Exec. Dir. of Medical Research Operations Purdue Pharma, L.P. Craig Lipset Head of Clinical Innovation, Worldwide Research & Development Pfizer Greg MacMichael, Ph.D. Global Head of Biologics Process R&D; Novartis Jerold Martin Chairman Bio-Process Systems Alliance (BPSA) John Orloff, M.D. Senior VP, CMO, Global Development Novartis Pharma AG Tina Morris, Ph.D. VP, Biologics and Biotechnology USP Division of Documentary Standards Mark Pykett, Ph.D. President and CEO Navidea Biopharmaceuticals Bernard Munos Founder, InnoThink Center for Research in Biomedical Innovation James Robinson VP, Vaccine & Biologics Technical Operations, Merck Mike Myatt Leadership Adviser, N2growth Mark Snyder, Ph.D. Former Associate Director, Purification Process Development Bayer HealthCare Carol Nacy, Ph.D. CEO, Sequella, Inc. Leslie Williams Founder, President, and CEO ImmusanT Sesha Neervannan, Ph.D. VP Pharmaceutical Development Allergan Kenneth Newman, M.D. CMO, Exec. VP, Clinical Dev. and Medical Affairs, Acton Pharmaceuticals Kevin O'Donnell Senior Partner, Exelsius Cold Chain Mgt. Consultancy US, Chair Int. Air Transport Assoc. Time & Temp. Task Force Ann Willmoth General Manager Blue Standard Consulting Angela Yochem Former CTO AstraZeneca WIN A COPY OF THIS BOOK! Ask the Board wants to hear from you. Have a question that you would like to pose to our editorial advisory board of experts? Send it to atb@lifescienceconnect.com. If we select your question for publication, we will provide you with a complimentary copy of a business book or CD, such as Mike Myatt's Leadership Matters — The CEO Survival Manual. ASK THE BOARD Have a response to our experts' answers? Send us an email to atb@lifescienceconnect.com. Q: What is the biggest mistake you have seen a c-level leader make? One thing I see occur with some regularity is the lack of collaboration in the c-suite. I hold the CEO accountable. The CEO may ask the executive team to work together but does not hold them accountable when they do not. Therefore they drift into their own silos and act more territorially than cross-functionally. It's the CEO who must insist that senior executives meet formally and informally to share insights and expertise with one another. Naturally there is a hesitation to meddle, but diversity of thought emerges from diversity of discipline. The CEO must follow through and ask the team how they are collaborating and what they have to show from the collaboration. Such a discussion elevates the issue and makes it actionable. First, use scientists and patients to teach the value pharma brings to healthcare. The R&D; of new medicines is a difficult process. No one can teach this better than the scientists who work on these programs. Second, make clinical trial results available in a timely fashion. Industry critics are eroding public trust by complaining that pharma has been slow to make trial results available. The public is becoming convinced the industry is hiding negative data. Greater transparency will show this to be false. Third, stop the illegal detailing of drugs. There is nothing more demoralizing than to hear that a company has been fined billions of dollars for breaking the law, which further convinces the public that pharma is run by shady operators. Finally, drop the TV ads. Though informative, the problem is most are distasteful with many of the ads discussing side effects. John Baldoni Baldoni is an internationally recognized leadership development consultant, executive coach, author, and speaker. John teaches men and women to achieve positive results by focusing on communication, influence, motivation, and supervision. 8 Q: What specifically should pharma do to repair its broken image? John LaMattina, Ph.D. LaMattina is the former senior VP at Pfizer Inc. and the president of Pfizer Global Research and Development. In this role, he oversaw the drug discovery and development efforts of more than 12,000 colleagues. LifeScienceLeader.com July 2013 Q: Beyond the typical benefits of centralized data storage and scalability, do cloud-based tools offer any other practical applications for the pharma industry? Cloud-based tools play a key role as pharma looks to virtual patient communities and the data these communities generate for indicators of patient outcomes in clinical trials. Eventually, the data generated by advanced sensor/actuator technology in the smartphones and other devices used by patients will find its way to the cloud for analysis and mining, perhaps by pharmas again in the context of a trial or related investigation. Finally, the scientific advances in genetics and simulation will be much more powerful when made searchable/analyzable in a cloud-based environment, and we'll see the impact of that in the next couple of years across the broader community. Angela Yochem Yochem previously was the CTO at AstraZeneca, where she formed strategic partnerships to drive innovation and business advantage through technology. She also has held senior roles at Dell, Bank of America, SunTrust, UPS, and IBM.